Presence of katG gene in resistant *Mycobacterium tuberculosis*  

M Jaber, A Rattan, R Kumar  

Abstract  
It has been reported recently that isoniazid resistant strains of *Mycobacterium tuberculosis* have lost the katG gene which encodes the catalase-peroxidase enzyme. A 35 mer oligonucleotide probe specific for the katG gene of *M. tuberculosis*, 3' end-labelled with digoxigenin, was constructed and hybridised with DNA extracted from 26 clinical isolates of *M. tuberculosis* under high stringency conditions. Twenty two of these isolates were resistant to 0.2 μg/ml isoniazid and 20 to 1.0 μg/ml isoniazid. Semi quantitative detection of catalase did not show any discrimination between isoniazid sensitive and resistant strains. The katG gene was present in all clinical strains of *M. tuberculosis*. Therefore, complete deletion of the katG gene does not seem to be the mechanism of isoniazid resistance in *M. tuberculosis* strains isolated from patients in India.  

(J Clin Pathol 1996;49:945–947)  

Keywords: *Mycobacterium tuberculosis*, isoniazid, catalase-peroxidase enzyme, katG gene, isoniazid resistance.

Isonicotinic acid hydrazide or isoniazid was first described in 1912, though its powerful activity against *Mycobacterium tuberculosis* was not recognised until 1951. The minimal inhibitory concentration (MIC) of isoniazid is extremely low (0.02–0.05 μg/ml) and this undoubtedly contributes to its efficacy.

Shortly after the introduction of isoniazid, it was noted that some highly resistant clinical isolates lacked the haem containing enzyme catalase-peroxidase (hydroperoxidase I) and were often avirulent in the guinea pig model. It is now known that the toxicity of isoniazid results from a peroxidation reaction that is catalysed by the enzyme catalase-peroxidase, which is encoded by the katG gene. Compelling evidence for a link between catalase-peroxidase and resistance to isoniazid came from the finding that some highly resistant isolates of *M. tuberculosis* lacked the katG gene.

The aim of the present study was to investigate the feasibility of rapid detection of isoniazid resistance by detecting katG gene deletion in DNA extracted from clinical isolates of *M. tuberculosis*.

Methods  
**BACTERIAL ISOLATES**  
Sputum samples from 257 consecutive patients were processed for the isolation of mycobacteria. Decontaminated and concentrated samples were inoculated onto two slopes of Lowenstein-Jensen medium. All isolates were identified to species level using conventional biochemical tests. Catalase was detected using a semiquantitative method. Drug susceptibility to isoniazid was measured using the Middlebrook agar proportionate method.

**EXTRACTION OF DNA FROM M TUBERCULOSIS**  
*M. tuberculosis* DNA was extracted from clinical isolates using the guanidinium hydrochloride lysis method. Briefly, 60–120 mg mycobacterial culture was transferred from a Lowenstein-Jensen slant to a screw capped glass tube containing 1 ml lysis buffer (6 M guanidinium hydrochloride; 50 mM EDTA; 1 mM 2-mercaptoethanol; 0.05% Tween 80) and three glass beads, vortexed to suspend the bacterial cells and transferred to an Eppendorf tube which was incubated at 4°C for 30 minutes and then immediately transferred to a water bath set at 75°C for 30 minutes. Debris was removed by centrifugation at 10 000 × g at 4°C for 10 minutes and the supernatant was transferred into another Eppendorf tube. DNA was precipitated in the supernatant with 0.5 volume of ice cold ethanol and kept at −20°C for one hour. After centrifugation at 12 000 × g for 15 minutes, the DNA pellet was redissolved in 0.8 ml lysis buffer without Tween 80. DNA was extracted first with phenol/chloroform (1/1, v/v) and then with chloroform/isomyl alcohol (24/1, v/v). 5 M NaCl was added to a final concentration of 0.3 M. DNA was precipitated with 2 volumes ethanol, kept for 20 minutes or overnight at −20°C. After centrifuging at 12 000 × g for 15 minutes. DNA was washed with 1 ml 70% ice cold ethanol, the DNA pellet was dried and dissolved in TE buffer (pH 8.0) (60–120 μl). The yield of DNA extracted from 60–120 mg bacteria...
ranged from 84 to 278 μg and the purity ranged from 1.84 to 2 (average 1.9).

To determine the specificity of the probe, DNA was also extracted from *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *S pyogenes*, *Salmonella typhi*, *S typhimurium*, and *Bacillus stearothermophilus* from our laboratory stock cultures.

**SELECTION AND SYNTHESIS OF THE OLGONUCLEOTIDE PROBE**

The probe was selected by obtaining the nucleotide sequences of the katG gene of *E coli*, *B stearothermophilus*, *S typhimurium*, and *M tuberculosis* from European Molecular Biology Laboratories (EMBL), Heidelberg, and aligning them. A 35 mer sequence, 5'-CGCT GCGGGTTGATCCGATCTATGAGCGGA TCACG-3' was selected as being specific for the *M tuberculosis* katG gene and did not have significant homology with katG sequences from other bacteria. The oligonucleotide probe was then synthesised (Bangalore Genie) and labelled using the digoxigenin oligonucleotide tailing kit (Boehringer Mannheim).

**HYBRIDISATION WITH katG PROBE**

Hybridisation was carried out at 68°C for six hours in 5× SSC on nylon membranes. The membrane was washed twice for five minutes each at 68°C with 2× SSC, 0.1% SDS followed by two washings with 0.1× SSC, 0.1% SDS. The hybridised probe was visualised using nitroblue tetrazolium and X-phosphate as described by the manufacturer (Boehringer Mannheim).

**Results**

Of the 257 samples examined, 56 were smear positive and 29 were both smear and culture positive. Twenty six isolates were identified as *M tuberculosis*. The remaining three were *M scrofulaceum* in two cases and *M fortuitum* in one.

Only four of the 26 isolates of *M tuberculosis* were susceptible to 0.2 μg/ml isoniazid and six to 1 μg/ml isoniazid; 20 were resistant. In the semiquantitative test for the presence of catalase, the height of bubbles produced by all isolates was less than 20 mm and therefore all were negative. However, this test did not differentiate between isoniazid sensitive and isoniazid resistant isolates (fig 1).

The probe, under high stringency conditions, hybridised only with DNA extracted from *M tuberculosis* but did not differentiate between isoniazid susceptible and isoniazid resistant strains as it hybridised to all 26 isolates of *M tuberculosis* (fig 2).

**Discussion**

Several hypotheses have been proposed to explain the relation between catalase-peroxidase activity and isoniazid resistance in *M tuberculosis*. Zhang et al provided evidence that the lack of catalase expression in *M tuberculosis* was important in some isoniazid resistant strains. They showed that two of three high level resistant *M tuberculosis* strains (MIC > 50 μg/ml) lacked the katG gene and concluded that in a subset of isoniazid resistant strains, the lack of catalase activity was due to the complete loss of the katG gene.

It has been suggested that isoniazid interacts with catalase-peroxidase and is converted by the peroxidase activity into a toxic derivative which acts at a second, as yet unknown, site. Most bacteria contain two catalases, one of which is a broad spectrum enzyme endowed with peroxidase activity (hydroperoxidase I). The second catalase (hydroperoxidase II), which by preferentially removing *H₂O₂* limits the ability of catalase-peroxidase to oxidize isoniazid. As *M tuberculosis* lacks the latter activity, its catalase-peroxidase enzyme can convert isoniazid into the lethal form without competition for the electron acceptor. The deletion of katG gene encoding the catalase-peroxidase enzyme would therefore make the strain resistant to isoniazid.

Convincing evidence for the central role of katG gene in conferring susceptibility in *M tuberculosis* was provided when isoniazid resistant isolates of *M tuberculosis* could be transformed with a plasmid vector carrying the functional katG gene. Expression of katG restored full drug susceptibility in isolates initially resistant to concentrations ranging from 3.2 to > 50 μg/ml isoniazid. However, Stoeckle et al., using PCR, found that 31 (76%) of the 41 isoniazid resistant strains in New York city contained katG sequences. Altamirano et al. amplified a 237 base pair sequence of the katG gene of one isoniazid susceptible and nine isoniazid resistant isolates by PCR. Amplification was observed in the isoniazid susceptible as well as in eight of the
nine isoniazid resistant isolates. DNA sequencing showed that eight of the nine isolates had a point mutation, deletion or insertion of one to three bases only.

Our probe for the \( M \) tuberculosis katG gene hybridised with all 26 smear and culture positive clinical isolates of \( M \) tuberculosis, indicating that the katG gene was not deleted completely in any of the 20 isoniazid resistant strains. These three studies taken together suggest that complete deletion of the katG gene does not seem to be the underlying mechanism of isoniazid resistance. Our probe, though specific for \( M \) tuberculosis, cannot be used as a marker for isoniazid susceptibility.

The authors wish to acknowledge the support and advice provided by Professor P N Tandon, Professor of Neurosurgery, AIIMS, Dr Rama Mukherjee, Deputy Director, NIR, Dr V M Katoch, Deputy Director, JALMA, and Dr Bimal K Das, Department of Microbiology, AIIMS, during the course of this work. Financial support from the Department of Biotechnology is gratefully acknowledged.

Abstract

In order to assess the benefits and limitations of pathology databases for cancer registries, computerised pathology records of malignant neoplasms diagnosed during 1992 were obtained for a defined area of Scotland for which pathology data were not routinely being used for cancer registration. Apparently 'missed' cancer registrations were identified by computerised probability matching with cancer registration records and their eligibility for registration was determined by reference to medical records, or when these were unavailable, by reference to the text of the original pathology report in conjunction with the local Community Health Index (to establish residency at the time of diagnosis). Misclassifications of site or incidence year were not regarded as 'missed' cases. Of 218 apparently 'missed' cancer registrations identified from computerised pathology records, 133 (5.7% of the revised total number of registrations for the study area in 1992) should have been registered. A further 14 cases were already registered but with misclassified site, morphology and/or behaviour codes. Ascertained


Benefits and limitations of pathology databases to cancer registries

D H Brewster, J Crichton, J C Harvey, G Dawson, E R Nairn

Abstract

In order to assess the benefits and limitations of pathology databases to cancer registries, computerised pathology records of malignant neoplasms diagnosed during 1992 were obtained for a defined area of Scotland for which pathology data were not routinely being used for cancer registration. Apparently 'missed' cancer registrations were identified by computerised probability matching with cancer registration records and their eligibility for registration was determined by reference to medical records, or when these were unavailable, by reference to the text of the original pathology report in conjunction with the local Community Health Index (to establish residency at the time of diagnosis). Misclassifications of site or incidence year were not regarded as 'missed' cases. Of 218 apparently 'missed' cancer registrations identified from computerised pathology records, 133 (5.7% of the revised total number of registrations for the study area in 1992) should have been registered. A further 14 cases were already registered but with misclassified site, morphology and/or behaviour codes. Ascertained

High quality cancer registration data are an essential prerequisite of any rational cancer control strategy. As about 81% of registrations in Scotland are verified histologically (unpublished data, 1994), pathology data represent a potentially excellent source of case ascertainment and offer the prospect of increasing the validity of diagnoses and the accuracy of information recorded about morphology.

In order to assess the benefits and limitations of computerised pathology data to a cancer registry, we studied a defined area of Scotland served by a single pathology laboratory whose data were not already being used for cancer data. Scottish Cancer Registry, Information and Statistics Division, Trinity Park House, South Trinity Road, Edinburgh EH3 3SQ

D H Brewster

J Crichton

J C Harvey

G Dawson

Department of Pathology, Crosshouse Hospital, Kilmarnock, Ayrshire KA1 0BE

E R Nairn

Correspondence to:

Dr D H Brewster.

Accepted for publication

12 August 1996

Keywords: neoplasms, pathology, registries.

Scottish Cancer Registry, Information and Statistics Division, Trinity Park House, South Trinity Road, Edinburgh EH3 3SQ

D H Brewster

J Crichton

J C Harvey

G Dawson

Department of Pathology, Crosshouse Hospital, Kilmarnock, Ayrshire KA1 0BE

E R Nairn

Correspondence to:

Dr D H Brewster.

Accepted for publication

12 August 1996

High quality cancer registration data are an essential prerequisite of any rational cancer control strategy. As about 81% of registrations in Scotland are verified histologically (unpublished data, 1994), pathology data represent a potentially excellent source of case ascertainment and offer the prospect of increasing the validity of diagnoses and the accuracy of information recorded about morphology.

In order to assess the benefits and limitations of computerised pathology data to a cancer registry, we studied a defined area of Scotland served by a single pathology laboratory whose data were not already being used for cancer


Presence of katG gene in resistant Mycobacterium tuberculosis.

M Jaber, A Rattan and R Kumar

J Clin Pathol 1996 49: 945-947
doi: 10.1136/jcp.49.11.945

Updated information and services can be found at:
http://jcp.bmj.com/content/49/11/945

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/